Attracting more capital into the UK health technology and life sciences industries is among the priorities of the Office for Life Sciences (OLS), as prescribed in the Life Sciences Industrial Strategy. (Also see "UK To Offset Brexit, Spur Global Growth With Life-Science Sector Deal And Industrial Strategy" - Medtech Insight, 27 November, 2017.)
An ongoing OLS program of work over the past 12 months has received input from industry and investors, with the collective goals of mapping of the funding environment and identifying...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?